Boston University School of Public Health, Slone Epidemiology Center at Boston University, and Massachusetts Center for Birth Defects Research and Prevention, Boston, Massachusetts.
Corresponding author: Samantha E. Parker, PhD, Boston University School of Public Health, 715 Albany Street, Boston, MA 02118; email: [email protected].
Supported in part by cooperative agreements U01DD000493 and U01DD001037 between the Birth Defects Branch of the Centers for Disease Control and Prevention and the Massachusetts Department of Public Health. Samantha E. Parker was supported by K01HL133600 from the National Institutes of Health. Coding of drug information in the National Birth Defects Prevention Study used the Slone Drug Dictionary under license from the Slone Epidemiology Center of Boston University.
Financial Disclosure Dr. Mitchell serves on the Tecfidera Pregnancy Registry Advisory Committee supported by Biogen. The other authors did not report any potential conflicts of interest.
Presented at the 48th Annual Meeting of the Society for Epidemiologic Research, June 16–19, 2015, Denver, Colorado; the 31st Annual International Conference on Pharmacoepidemiology and Therapeutic Risk Management, International Society for Pharmacoepidemiology, August 22–26, 2015, Boston, Massachusetts; and the 18th Annual Meeting of the National Birth Defects Prevention Network, October 19–20, 2015, Arlington, Virginia.
For a list of acknowledgments related to this study, see Appendix 1 online at https://links.lww.com/AOG/B102.
Each author has indicated that he or she has met the journal's requirements for authorship.
Received January 9, 2017. Received in revised form March 21, 2018. Accepted March 29, 2018.
